Physician profile
Rajdeep Singh
NPI 1104368778
$2,344.71
in general payments reported to CMS, 2019-2025
23 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,473 · 2022: $237 · 2023: $237 · 2024: $116 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $321.36 | 2021-2025 | |
| Novo Nordisk INC | $238.41 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $222.20 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $203.79 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $161.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $161.14 | 2021 | |
| Amgen INC. | $137.19 | 2021-2022 | |
| Lilly USA, LLC | $125.58 | 2021-2024 | Mounjaro |
| Abbott Laboratories | $119.69 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $112.04 | 2021-2022 | |
| Astellas Pharma US INC | $87.18 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.10 | 2021 | |
| Bausch Health US, LLC | $79.28 | 2021-2022 | |
| Glaxosmithkline, LLC. | $56.70 | 2021-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $40.33 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.33 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.02 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.59 | 2021 | |
| Amarin Pharma, INC. | $24.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.31 | 2021 | |
| Dexcom, INC. | $23.97 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $19.26 | 2022 | |
| Eisai INC. | $17.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajdeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.